Abstract

The current study tried to uncover the molecular mechanism of E3 ubiquitin ligase F-box and WD repeat domain-containing 7 (FBW7) in a heritable autoimmune disease, type I diabetes (T1D). After streptozotocin-induced T1D model establishment in non-obese diabetic (NOD) mouse, the protein expression of FBW7, enhancer of zeste homolog 2 (EZH2), and Zinc finger and BTB domain containing 16 (ZBTB16) was quantified. Next, splenocytes and pancreatic beta cells were isolated to measure the production of pro-inflammatory cytokines in splenocytes, as well as islet beta-cell apoptosis. Additionally, the stability of EZH2 induced by FBW7 was analyzed by cycloheximide chase assay. The binding affinity of FBW7 and EZH2 and the consequence of ubiquitination were monitored by co-immunoprecipitation assay. Last, a chromatin immunoprecipitation assay was employed to analyze the accumulation of EZH2 and H3K27me3 at the ZBTB16 promoter region. Our study demonstrated downregulated FBW7 and ZBTB16 and upregulated EZH2 in diabetic NOD mice. Overexpression of FBW7 in the NOD mice inhibited pro-inflammatory cytokine release in the splenocytes and the apoptosis of islets beta cells. FBW7 destabilized EZH2 and accelerated ubiquitin-dependent degradation. EZH2 and H3K27me3 downregulated the ZBTB16 expression by accumulating in the ZBTB16 promoter and methylation. FBW7 upregulates the expression of ZBTB16 by targeting histone methyltransferase EZH2 thus reducing the occurrence of T1D.

Highlights

  • Type I diabetes (T1D) is a heritable autoimmune disease [1]

  • The correlation between F-box and WD repeat domain-containing 7 (FBW7) and diabetic nephropathy has apoptosis decreased after overexpression FBW7 (OE-FBW7) treatment (Fig. 2F)

  • In the present study, the mechanism of enhancer of zeste homolog 2 (EZH2)/Zinc finger and BTB domain containing 16 (ZBTB16) in T1D inhibition by FBW7 is clarified, suggesting that FBW7 is a promising target for T1D therapy

Read more

Summary

Introduction

Type I diabetes (T1D) is a heritable autoimmune disease [1]. Caused by an autoimmune response against pancreatic beta cells, T1D results in beta cell destruction and may accompany another autoimmune disease [2]. T1D is generally considered a juvenileonset disease but it can occur at any age of life. Patients have to administrate insulin for survival causing a tremendous burden to individuals and society psychologically and economically [3]. T1D is a chronic autoimmune disease, which seriously impairs the pancreatic beta cells [4]. Healthcare providers are struggling for economic and standardized therapies

Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.